2025 Europe 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report
Description
The 2025 Europe 23-Valent Pneumococcal Vaccine Market Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in Europe are Pfizer Inc., Merck & Co., Inc., Sanofi Pasteur, and GlaxoSmithKline plc (GSK). Pfizer leads with its established pneumococcal conjugate vaccines like Prevnar 13 and has introduced the 20-valent vaccine PREVENAR 20 approved in Europe for infants and adults, strengthening its market dominance. Merck recently received European Commission approval for its 21-valent conjugate vaccine CAPVAXIVE, targeting adult pneumococcal disease, enhancing its position as a key player. Sanofi Pasteur and GSK focus on advanced research and broad vaccine portfolios, with GSK expanding through acquisitions like Affinivax to boost its pneumococcal vaccine offerings in Europe.
These companies benefit from Europe's growing pneumococcal vaccine demand driven by rising pneumonia cases and governmental vaccination programs. The market, valued over USD 1 billion in 2023 in Europe, is projected to grow at a CAGR exceeding 5% through 2030, highlighting continuing innovation and competition, particularly in conjugate vaccines that offer broader serotype coverage. These firms' focus on adult immunization, vaccine development (including higher-valency candidates), and strategic collaborations underpins their leading roles in the evolving pneumococcal vaccine landscape in Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the 23-valent Pneumococcal Vaccine Market by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively participating in the 23-valent pneumococcal vaccine market in Europe are Pfizer Inc., Merck & Co., Inc., Sanofi Pasteur, and GlaxoSmithKline plc (GSK). Pfizer leads with its established pneumococcal conjugate vaccines like Prevnar 13 and has introduced the 20-valent vaccine PREVENAR 20 approved in Europe for infants and adults, strengthening its market dominance. Merck recently received European Commission approval for its 21-valent conjugate vaccine CAPVAXIVE, targeting adult pneumococcal disease, enhancing its position as a key player. Sanofi Pasteur and GSK focus on advanced research and broad vaccine portfolios, with GSK expanding through acquisitions like Affinivax to boost its pneumococcal vaccine offerings in Europe.
These companies benefit from Europe's growing pneumococcal vaccine demand driven by rising pneumonia cases and governmental vaccination programs. The market, valued over USD 1 billion in 2023 in Europe, is projected to grow at a CAGR exceeding 5% through 2030, highlighting continuing innovation and competition, particularly in conjugate vaccines that offer broader serotype coverage. These firms' focus on adult immunization, vaccine development (including higher-valency candidates), and strategic collaborations underpins their leading roles in the evolving pneumococcal vaccine landscape in Europe.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
